Valuation

NOVNNovartis AG

StockStockSwitzerlandHealth careEU retail: available

−0.7% today · +26.2% over a year

10/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 99% of the instruments we score

Quality, Stability, Dividend safety: among the best of its peers; priced lower than most peers. Dividend yield 2.89%.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricNOVNSector medianvs median
P/E21.221.2 · n=11near the median
P/B6.41.8 · n=17256% above
P/S—3.5 · n=12—
EV/EBIT17.817.8 · n=10near the median
Free-cash-flow yield5.9%5.0% · n=1518% above
Dividend yield2.89%1.60% · n=5881% above
Return on equity31.0%4.5% · n=17590% above
Return on invested capital25.0%6.1% · n=14311% above
Gross margin—56.5% · n=9—

Value factor: 75 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

InstrumentP/EP/BEV/EBITFree-cash-flow yieldDividend yieldSmart Score
NVSNovartis AG21.36.517.95.9%3.1%9/10
SNYSanofi11.71.316.17.9%5.0%7/10
SANSanofi SA11.61.315.98.0%5.6%8/10
ALCAlcon35.11.627.65.0%0.5%3/10
ALCAlcon AG35.01.627.55.0%0.5%5/10
STESTERIS28.13.121.14.1%0.8%6/10
BNTXBioNTech SE—1.0—1.4%0.0%—/10
ICLRICON plc337.91.560.96.2%0.0%3/10
CRSPCRISPR Therapeutics AG—2.8—−7.7%0.0%1/10
ABCLAbCellera Biologics—3.9—−3.4%0.0%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 Dec 2025 · filed 04 Feb 2026